Abstract
The in vivo hollow fibre model was developed by the National Cancer Institute (NCI) in the United
States of America (USA) at a time when the number of potential anti-cancer drugs arising
from in vitro screening efforts exceeded the available capacity for testing in traditional xenograft
models. Updated analysis of the predictive value of the hollow fibre model continues
to indicate that the greater the response in the hollow fibre assay, the more likely
it is that activity will be seen in subsequent xenograft models. The original 12 cell
line hollow fibre panel has been supplemented with histology-specific panels, and
we begin here to analyse their utility in predicting activity in subsequent in vivo models. The key goal of using the hollow fibre model as a way to decrease the cost,
both financial and in the number of animals used, to evaluate initial evidence of
a compound's capacity to act across physiological barriers continues to be reinforced
with our enlarging experience.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.J. Natl. Cancer Inst. 1991; 83: 757-766
- Display and analysis of patterns of differential activity of drugs against human tumor cell lines.J. Natl. Cancer Inst. 1989; 81: 1088-1092
- In vivo cultivation of tumor cells in hollow fibers.Life Sci. 1995; 57: 131-141
- Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.Brit. J. Cancer. 2001; 84: 1424-1431
- Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells.Cancer Res. 1998; 58: 5263-5266
- The hollow fiber assay.Anticancer Res. 2000; 20: 903-911
- Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture.Cancer Res. 1991; 51: 1247-1256
- Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA.Ann. Oncol. 1999; 10: 1287-1291
- A potential role for imaging technology in anticancer efficacy evaluations.Eur. J. Cancer. 2004; 40 (this issue): 6
Article info
Publication history
Accepted:
November 17,
2003
Received:
October 27,
2003
Identification
Copyright
© 2004 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.
